KaydedilenlerDerginizi ekleyin

Dergiler / NanoEra / 2024 / Volume: 4 Issue: 2

Functionalized liposomes for colorectal cancer therapy

Leila Rezaee Uonaki(Kurdistan University of Medical Sciences)0000-0003-4160-7872
Farideh Ghalamfarsa(Kurdistan University of Medical Sciences)0000-0002-0127-1326
Yousef Fazli(Dena Pathobiology Laboratory)0000-0002-8003-9233
Ramin Jannesar(Yasuj University of Medical Sciences)0000-0002-4928-7239
Ghasem Ghalamfarsa(Yasouj University)0000-0002-5554-6268
Ahmet Hacımüftüoğlu(ATATURK UNIVERSITY)0000-0002-9658-3313
Azizeh Shadidizaji(ATATURK UNIVERSITY)0000-0002-1996-7823
Kağan Tolga Cinisli(ATATURK UNIVERSITY)0000-0003-3909-9637
Mobina Shahsafi(DOKUZ EYLUL UNIVERSITY)0009-0007-2652-1487
Dergi
NanoEra
Sayfa
—
Yayın Tarihi
2024-12-20
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Nanoliposome carriers have enormous potential to overcome the present constraints of cancer treatment, and the creation of this technology gives new possibilities in CRC treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Colorectal cancer (CRC) is one of the most common cancers.
📊
Temel Bulgular & Veri:An effective strategy to increase the effectiveness of the treatment ofthis cancer is the use of a liposomal delivery system, which provides the possibility of providing hydrophobic and hydrophilic compounds with better biocompatibility and reduction of side effects by using several advantages, thus causing anti-cancer activity.
💡
Sonuç & Katkı:Nanoliposome carriers have enormous potential to overcome the present constraints of cancer treatment, and the creation of this technology gives new possibilities in CRC treatment.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Colorectal cancer · Liposomal delivery system · Cancer treatment

Abstract

Colorectal cancer (CRC) is one of the most common cancers. Many patients do not live for several years following their diagnosis, highlighting the urgent need for new treatment options, including new drug delivery methods. An effective strategy to increase the effectiveness of the treatment ofthis cancer is the use of a liposomal delivery system, which provides the possibility of providing hydrophobic and hydrophilic compounds with better biocompatibility and reduction of side effects by using several advantages, thus causing anti-cancer activity. Better tumor, drug accumulation is longer and they do not show any cytotoxic effect on normal cells. In this review, we will present nanoliposomes containing various compounds and ligands studied in CRC treatment. We will discuss on the benefits of liposomal administration in various forms, along with their effectiveness, specificity, and drug accumulation. Nanoliposome carriers have enormous potential to overcome the present constraints of cancer treatment, and the creation of this technology gives new possibilities in CRC treatment.

🔖

Bu Makaleye Atıf Yap

Uonaki, L. R., Ghalamfarsa, F., Fazli, Y., Jannesar, R., Ghalamfarsa, G., Hacımüftüoğlu, A., Shadidizaji, A., Cinisli, K. T., Shahsafi, M. (2024). Functionalized liposomes for colorectal cancer therapy. NanoEra, Volume: 4 Issue: 2. https://doi.org/10.5281/zenodo.14534004

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (133)

  1. Bansal D, Gulbake A, Tiwari J, Jain SK. Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer. Int J Biol Macromol. 2016;82:687-695. doi:10.1016/j.ijbiomac.2015.09.052
  2. Lohlamoh W, Soontornworajit B, Rotkrua P. Anti￾Proliferative Effect of Doxorubicin-Loaded AS1411 Aptamer on Colorectal Cancer Cell. Asian Pacific J Cancer Prev. 2021;22(7):2209-2219. doi:10.31557/APJCP.2021.22.7.2209
  3. Etissa EK, Assefa M, Ayele BT. Prognosis of colorectal cancer in Tikur Anbessa Specialized Hospital, the only oncology center in Ethiopia. Chuu C-P, ed. PLoS One. 2021;16(2):e0246424. doi:10.1371/journal.pone.0246424
  4. Naeimi R, Najafi R, Molaei P, Amini R, Pecic S. Nanoparticles: The future of effective diagnosis and treatment of colorectal cancer? Eur J Pharmacol. 2022;936:175350. doi:10.1016/j.ejphar.2022.175350
  5. Yu T, Wu C, Zhu C, et al. Oral Administration of Liposome￾Apatinib and Locally Delivery of Docetaxel/MPEG-PCL by Fibrin Glue Synergistically Improve Therapeutic Effect in Colorectal Cancer. J Biomed Nanotechnol. 2018;14(12):2077-2091. doi:10.1166/jbn.2018.2651
  6. Huda S, Alam MA, Sharma PK. Smart nanocarriers-based drug delivery for cancer therapy: An innovative and developing strategy. J Drug Deliv Sci Technol. 2020;60:102018. doi:10.1016/j.jddst.2020.102018
  7. Enrico C. Nanotechnology-Based Drug Delivery of Natural Compounds and Phytochemicals for the Treatment of Cancer and Other Diseases. In:; 2019:91-123. doi:10.1016/B978-0-444-64185-4.00003-4
  8. Ali ES, Sharker SM, Islam MT, et al. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives. Semin Cancer Biol. 2021;69:52-68. doi:10.1016/j.semcancer.2020.01.011
  9. Haidar ZS. Polymicellar-based drug delivery systems for use in nanodentistry. Biofunctional Mater. Published online March 29, 2023. doi:10.55092/bm20230003
  10. Vyas K, Rathod M, Patel MM. Insight on nano drug delivery systems with targeted therapy in treatment of oral cancer. Nanomedicine Nanotechnology, Biol Med. 2023;49:102662. doi:10.1016/j.nano.2023.102662
  11. Kumari S, Goyal A, Sönmez Gürer E, et al. Bioactive Loaded Novel Nano-Formulations for Targeted Drug Delivery and Their Therapeutic Potential. Pharmaceutics. 2022;14(5):1091. doi:10.3390/pharmaceutics14051091
  12. Afarid M, Mahmoodi S, Baghban R. Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update. J Nanobiotechnology. 2022;20(1):361. doi:10.1186/s12951-022-01567-7
  13. Sen K, Banerjee S, Mandal M. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer. Colloids Surfaces B Biointerfaces. 2019;180:9-22. doi:10.1016/j.colsurfb.2019.04.035
  14. Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target. 2019;27(7):742-761. doi:10.1080/1061186X.2018.1527337
  15. Ge L, Tan X, Sheng R, Xiao J. Layer-by-layer self-assembly of giant polyelectrolyte microcapsules templated by microbubbles as potential hydrophilic or hydrophobic drug delivery system. Colloid Interface Sci Commun. 2022;47:100603. doi:10.1016/j.colcom.2022.100603
  16. Musielak E, Feliczak-Guzik A, Nowak I. Synthesis and Potential Applications of Lipid Nanoparticles in Medicine. Materials (Basel). 2022;15(2):682. doi:10.3390/ma15020682
  17. Beltrán-Gracia E, López-Camacho A, Higuera-Ciapara I, Velázquez-Fernández JB, Vallejo-Cardona AA. Nanomedicine review: clinical developments in liposomal Bansal D, Gulbake A, Tiwari J, Jain SK. Development of liposomes entrapped in alginate beads for the treatment of colorectal cancer. Int J Biol Macromol. 2016;82:687-695. doi:10.1016/j.ijbiomac.2015.09.052
  18. Bozzuto G, Molinari A. Liposomes as nanomedical devices. Int J Nanomedicine. Published online February 2015:975. doi:10.2147/IJN.S68861
  19. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics. 2017;9(2):12. doi:10.3390/pharmaceutics9020012
  20. Ilfeld BM, Eisenach JC, Gabriel RA. Clinical Effectiveness of Liposomal Bupivacaine Administered by Infiltration or Peripheral Nerve Block to Treat Postoperative Pain. Anesthesiology. 2021;134(2):283-344. doi:10.1097/ALN.0000000000003630
  21. Olusanya T, Haj Ahmad R, Ibegbu D, Smith J, Elkordy A. Liposomal Drug Delivery Systems and Anticancer Drugs. Molecules. 2018;23(4):907. doi:10.3390/molecules23040907
  22. Dragovich T, Mendelson D, Kurtin S, Richardson K, Von Hoff D, Hoos A. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemother Pharmacol. 2006;58(6):759-764. doi:10.1007/s00280-006-0235-4
  23. Pola R, Pokorná E, Vočková P, et al. Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma. Acta Biomater. 2021;119:349-359. doi:10.1016/j.actbio.2020.11.014
  24. Moradi Kashkooli F, Jakhmola A, Hornsby TK, Tavakkoli J (Jahan), Kolios MC. Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions. J Control Release. 2023;355:552-578. doi:10.1016/j.jconrel.2023.02.009
  25. Mojarad-Jabali S, Mahdinloo S, Farshbaf M, et al. Transferrin receptor-mediated liposomal drug delivery: recent trends in targeted therapy of cancer. Expert Opin Drug Deliv. 2022;19(6):685-705. doi:10.1080/17425247.2022.2083106
  26. Zhao Y, Zhang Z, Pan Z, Liu Y. Advanced bioactive nanomaterials for biomedical applications. Exploration. 2021;1(3). doi:10.1002/EXP.20210089
  27. Din F ud, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine. 2017;Volume 12:7291-7309. doi:10.2147/IJN.S146315
  28. Bigdeli A, Makhmalzadeh BS, Feghhi M, SoleimaniBiatiani E. Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation. Drug Deliv Transl Res. 2023;13(4):1035-1047. doi:10.1007/s13346-022-01266-8
  29. Haneef J, Ali S, Chadha R. Emerging Multi-Drug Eutectics: Opportunities and Challenges. AAPS PharmSciTech. 2021;22(2):66. doi:10.1208/s12249-021-01939-6
  30. Gu W, Meng F, Haag R, Zhong Z. Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation. J Control Release. 2021;329:676-695. doi:10.1016/j.jconrel.2020.10.003
  31. Tangsiri M, Hheidari A, Liaghat M, et al. Promising applications of nanotechnology in inhibiting chemo￾resistance in solid tumors by targeting epithelial￾mesenchymal transition EMT). Biomed Pharmacother. 2024;170:115973. doi:10.1016/j.biopha.2023.115973
  32. Zhang N, Shu G, Qiao E, et al. DNA-Functionalized Liposomes In Vivo Fusion for NIR-II/MRI Guided Pretargeted Ferroptosis Therapy of Metastatic Breast Cancer. ACS Appl Mater Interfaces. 2022;14(18):20603-20615. doi:10.1021/acsami.2c01105
  33. Wang H, Huang Y. Combination therapy based on nano codelivery for overcoming cancer drug resistance. Med Drug Discov. 2020;6:100024. doi:10.1016/j.medidd.2020.100024
  34. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an Emerging Platform for Cancer Therapy. In: Nano-Enabled Medical Applications.; 2020.
  35. Peretz Damari S, Shamrakov D, Varenik M, et al. Practical aspects in size and morphology characterization of drug￾loaded nano-liposomes. Int J Pharm. 2018;547(1-2):648- 655. doi:10.1016/j.ijpharm.2018.06.037
  36. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. doi:10.3322/caac.20073
  37. Banerjee K, Banerjee S, Mandal M. Enhanced chemotherapeutic efficacy of apigenin liposomes in colorectal cancer based on flavone-membrane interactions. J Colloid Interface Sci. 2017;491:98-110. doi:10.1016/j.jcis.2016.12.025
  38. Kikuchi H, Yuan B, Hu X, Okazaki M. Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents. Am J Cancer Res. 2019;9(8):1517-1535. http://www.ncbi.nlm.nih.gov/pubmed/31497340
  39. Țigu AB, Toma V-A, Moț AC, et al. The Synergistic Antitumor Effect of 5-Fluorouracil Combined with Allicin against Lung and Colorectal Carcinoma Cells. Molecules. 2020;25(8):1947. doi:10.3390/molecules25081947
  40. Patras L, Sylvester B, Luput L, et al. Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo. Cancer Biol Ther. 2017;18(8):616-626. doi:10.1080/15384047.2017.1345392
  41. Shulpekova Y, Nechaev V, Kardasheva S, et al. The Concept of Folic Acid in Health and Disease. Molecules. 2021;26(12):3731. doi:10.3390/molecules26123731
  42. Yang C, Liu H-Z, Fu Z-X. Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in (Jahan), Kolios MC. Ultrasound-mediated nano drug delivery for treating cancer: Fundamental physics to future directions. J Control Release. 2023;355:552-578. doi:10.1016/j.jconrel.2023.02.009
  43. Tangsiri M, Hheidari A, Liaghat M, et al. Promising applications of nanotechnology in inhibiting chemo￾resistance in solid tumors by targeting epithelial￾mesenchymal transition (EMT). Biomed Pharmacother. 2024;170:115973. doi:10.1016/j.biopha.2023.115973
  44. Yang C, Liu H-Z, Fu Z-X. Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in doi:10.1016/j.biopha.2019.109142
  45. Zhang B, Wang T, Yang S, et al. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy. J Control Release. 2016;238:10-21. doi:10.1016/j.jconrel.2016.07.022
  46. Ding M, Zhang Y, Li J, Pu K. Bioenzyme-based nanomedicines for enhanced cancer therapy. Nano Converg. 2022;9(1):7. doi:10.1186/s40580-022-00297-8
  47. Miller B, Sewell-Loftin MK. Mechanoregulation of Vascular Endothelial Growth Factor Receptor 2 in Angiogenesis. Front Cardiovasc Med. 2022;8. doi:10.3389/fcvm.2021.804934
  48. Teleanu RI, Chircov C, Grumezescu AM, Teleanu DM. Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment. J Clin Med. 2019;9(1):84. doi:10.3390/jcm9010084
  49. Wang Z, Dabrosin C, Yin X, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35:S224-S243. doi:10.1016/j.semcancer.2015.01.001
  50. Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. How to Treat Melanoma? The Current Status of Innovative Nanotechnological Strategies and the Role of Minimally Invasive Approaches like PTT and PDT. Pharmaceutics. 2022;14(9):1817. doi:10.3390/pharmaceutics14091817
  51. Mir SA, Padhiary A, Pati A, et al. Potential phytochemicals as microtubule-disrupting agents in cancer prevention. In: Recent Frontiers of Phytochemicals. Elsevier; 2023:225- 246. doi:10.1016/B978-0-443-19143-5.00020-7
  52. A. Razak SA, Mohd Gazzali A, Fisol FA, et al. Advances in Nanocarriers for Effective Delivery of Docetaxel in the reatment of Lung Cancer: An Overview. Cancers (Basel). 2021;13(3):400. doi:10.3390/cancers13030400
  53. Hu Y, Wu C, Zhu C, et al. Enhanced uptake and improved anti-tumor efficacy of doxorubicin loaded fibrin gel with liposomal apatinib in colorectal cancer. Int J Pharm. 2018;552(1-2):319-327. doi:10.1016/j.ijpharm.2018.10.013
  54. Sesarman A, Tefas L, Sylvester B, et al. Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment. Drug Deliv Transl Res. 2019;9(1):260-272. doi:10.1007/s13346-018-00598-8
  55. Verma V, Sharma S, Gaur K, Kumar N. Role of vinca alkaloids and their derivatives in cancer therapy. World J Adv Res Rev. 2022;16(3):794-800.
  56. Zhang T, Ma L, Wu P, et al. Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non‑small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway. Oncol Rep. Published online January 22, 2019. doi:10.3892/or.2019.6976
  57. Aborehab NM, Osama N. Effect of Gallic acid in potentiating chemotherapeutic effect of Paclitaxel in HeLa cervical cancer cells. Cancer Cell Int. 2019;19(1):154. doi:10.1186/s12935-019-0868-0
  58. Mirazimi SMA, Dashti F, Tobeiha M, et al. Application of Quercetin in the Treatment of Gastrointestinal Cancers. Front Pharmacol. 2022;13. doi:10.3389/fphar.2022.860209
  59. Al-Halaseh LK, Al-Jawabri NA, Al-Btoush H, et al. In vivo investigation of the potential hypoglycemic activity of Pennisetum setaceum: Justification of the traditional use among Jordanians. Res J Pharm Technol. Published online July 29, 2022:3185-3189. doi:10.52711/0974-360X.2022.00533
  60. Khorsandi K, Kianmehr Z, Hosseinmardi Z, Hosseinzadeh R. Anti-cancer effect of gallic acid in presence of low level laser irradiation: ROS production and induction of apoptosis and ferroptosis. Cancer Cell Int. 2020;20(1):18. doi:10.1186/s12935-020-1100-y
  61. Maleki Dana P, Sadoughi F, Asemi Z, Yousefi B. Anti-cancer properties of quercetin in osteosarcoma. Cancer Cell Int. 2021;21(1):349. doi:10.1186/s12935-021-02067-8
  62. Muhammad N, Steele R, Isbell TS, Philips N, Ray RB. Bitter melon extract inhibits breast cancer growth in preclinical model by inducing autophagic cell death. Oncotarget. 2017;8(39):66226-66236. doi:10.18632/oncotarget.19887
  63. Maurya DK, Nandakumar N, Devasagayam TPA. Anticancer property of gallic acid in A549, a human lung adenocarcinoma cell line, and possible mechanisms. J Clin Biochem Nutr. 2010;48(1):85-90. doi:10.3164/jcbn.11-004FR
  64. Al-Samydai A, Al Qaraleh M, Al Azzam KM, et al. Formulating co-loaded nanoliposomes with gallic acid and quercetin for enhanced cancer therapy. Heliyon. 2023;9(6):e17267. doi:10.1016/j.heliyon.2023.e17267
  65. Russo E, Scicchitano F, Whalley BJ, et al. Hypericum perforatum: Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug-Drug Interactions. Phyther Res. 2014;28(5):643-655. doi:10.1002/ptr.5050
  66. Stojanovic G, Dordevic A, Smelcerovic A. Do Other Hypericum Species Have Medical Potential As St. John’s Wort (Hypericum perforatum)? Curr Med Chem. Wang Z, Dabrosin C, Yin X, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol. 2015;35:S224-S243. doi:10.1016/j.semcancer.2015.01.001
  67. Rezaeinejad F, Bardania H, Ghalamfarsa F, Hasanzadeh S, Jadidi-Niaragh F, Ghalamfarsa G. Proapoptotic effect of nanoliposomes loaded with hydroalcoholic extract of Hypericum perforatum L. in combination with curcumin on SW48 and SW1116 colorectal cancer cell lines. J Med Plants. 2022;21(82):28-42. doi:10.52547/jmp.21.82.28
  68. Rastgoo M, Hosseinzadeh H, Alavizadeh H, Abbasi A, Ayati Z, Jaafari M. Antitumor Activity of PEGylated Nanoliposomes Containing Crocin in Mice Bearing C26 Colon Carcinoma. Planta Med. 2013;79(06):447-451. doi:10.1055/s-0032-1328363
  69. Abdullaev FI. Cancer Chemopreventive and Tumoricidal Properties of Saffron (Crocus sativus L.). Exp Biol Med. 2002;227(1):20-25. doi:10.1177/153537020222700104
  70. Tavakkol-Afshari J, Brook A, Mousavi SH. Study of cytotoxic and apoptogenic properties of saffron extract in human cancer cell lines. Food Chem Toxicol. 2008;46(11):3443-3447. doi:10.1016/j.fct.2008.08.018
  71. Prasad S, Tyagi AK. Ginger and Its Constituents: Role in Prevention and Treatment of Gastrointestinal Cancer. Gastroenterol Res Pract. 2015;2015:1-11. 99 doi:10.1155/2015/142979
  72. Saeedifar AM, Mosayebi G, Ghazavi A, Ganji A. Synergistic Evaluation of Ginger and Licorice Extracts in a Mouse Model of Colorectal Cancer. Nutr Cancer. 2021;73(6):1068-1078. doi:10.1080/01635581.2020.1784440
  73. Yavari M, Jaafari MR, Mirzavi F, Mosayebi G, Ghazavi A, Ganji A. Anti-tumor effects of PEGylated-nanoliposomes containing ginger extract in colorectal cancer-bearing mice. Iran J Basic Med Sci. 2022;25(7):890-896. doi:10.22038/IJBMS.2022.63870.14075
  74. Sefidkon F, Sagvand BT, Naderi M, Ghooshegir S. Comparison of anticancer effects of nanocapsules of Nasturtium officinalis (L.) R. Br. extract with methanolic extract and its fractions. Iran J Med Aromat Plants Res. 2013;29(1):35-50. doi:https://doi.org/10.22092/ijmapr.2013.2876
  75. Adlravan E, Sepideh jalilzadeh-Razin, Nejati K, et al. Potential activity of free and PLGA/PEG nanoencapsulated nasturtium officinale extract in inducing cytotoxicity and apoptosis in human lung carcinoma A549 cells. J Drug Deliv Sci Technol. 2021;61:102256. doi:10.1016/j.jddst.2020.102256
  76. Taghavinia F, Teymouri F, Farokhrouz F, et al. Nanoliposome-Loaded Phenolics from Nasturtium officinale Improves Health Parameters in a Colorectal Cancer Mouse Model. animals. 2022;12(24):3492. doi:10.3390/ani12243492
  77. Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer. 2019;125(23):4139-4147. doi:10.1002/cncr.32163
  78. Das A, Adhikari S, Deka D, et al. An Updated Review on the Role of Nanoformulated Phytochemicals in Colorectal Cancer. Medicina (B Aires). 2023;59(4):685. doi:10.3390/medicina59040685
  79. Maniewska J, Jeżewska D. Non-Steroidal Anti-Inflammatory Drugs in Colorectal Cancer Chemoprevention. Cancers (Basel). 2021;13(4):594. doi:10.3390/cancers13040594
  80. Khalil HE, Ibrahim H-IM, Ahmed EA, Emeka PM, Alhaider IA. Orientin, a Bio-Flavonoid from Trigonella hamosa L., Regulates COX-2/PGE-2 in A549 Cell Lines via miR-26b and miR-146a. Pharmaceuticals. 2022;15(2):154. doi:10.3390/ph15020154
  81. Sun P, Quan J-C, Wang S, et al. lncRNA-PACER upregulates COX-2 and PGE2 through the NF-κB pathway to promote the proliferation and invasion of colorectal-cancer cells. Gastroenterol Rep. 2021;9(3):257-268. doi:10.1093/gastro/goaa060
  82. Nkadimeng SM, Steinmann CM, Eloff JN. Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells. J Inflamm Res. 2021;Volume 14:3729-3738. doi:10.2147/JIR.S317182
  83. Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci. 2022;9. doi:10.3389/fmolb.2022.847835
  84. Fu J, Lv Y, Jia Q, et al. Purification and determination of antibody drugs in bio-samples by EGFR/cell membrane chromatography method. J Pharm Biomed Anal. 2022;217:114808. doi:10.1016/j.jpba.2022.114808
  85. Jahani V, Yazdani M, Badiee A, Jaafari MR, Arabi L. Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma. J Control Release. 2023;354:453-464. doi:10.1016/j.jconrel.2023.01.034
  86. Raab WJ. CDX2 as a predictive biomarker of drug response in colon cancer. Published online 2021.
  87. Zalba S, Contreras AM, Haeri A, et al. Cetuximab￾oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer. J Control Release. 2015;210:26-38. doi:10.1016/j.jconrel.2015.05.271
  88. Brzozowska E, Deshmukh S. Integrin Alpha v Beta 6 (αvβ6) and Its Implications in Cancer Treatment. Int J Mol Sci. 2022;23(20):12346. doi:10.3390/ijms232012346
  89. Liang B, Shahbaz M, Wang Y, et al. Integrinβ6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma. Clin Cancer Res. 2015;21(5):1183-1195. doi:10.1158/1078-0432.CCR-14-1194
  90. Sompel K, Elango A, Smith AJ, Tennis MA. Cancer chemoprevention through Frizzled receptors and EMT. Discov Oncol. 2021;12(1):32. doi:10.1007/s12672-021-00429-2
  91. Scavo MP, Cigliano A, Depalo N, et al. Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer. J Oncol. 2019;2019:1-12. doi:10.1155/2019/2715968
  92. Scavo MP, Depalo N, Rizzi F, et al. FZD10 Carried by Exosomes Sustains Cancer Cell Proliferation. Cells. 2019;8(8):777. doi:10.3390/cells8080777
  93. Ueno K, Hiura M, Suehiro Y, et al. Frizzled-7 as a Potential Therapeutic Target in Colorectal Cancer. Neoplasia. 2008;10(7):697-705. doi:10.1593/neo.08320
  94. Wong SCC, He CW, Chan CML, et al. Clinical Significance of Frizzled Homolog 3 Protein in Colorectal Cancer Patients. Katoh M, ed. PLoS One. 2013;8(11):e79481. doi:10.1371/journal.pone.0079481
  95. Zeng C-M, Chen Z, Fu L. Frizzled Receptors as Potential Therapeutic Targets in Human Cancers. Int J Mol Sci. 2018;19(5):1543. doi:10.3390/ijms19051543
  96. Nagayama S, Yamada E, Kohno Y, et al. Inverse correlation of the up‐regulation of FZD10 expression and the activation of β‐catenin in synchronous colorectal tumors. Cancer Sci. 2009;100(3):405-412. doi:10.1111/j.1349-7006.2008.01052.x
  97. Scavo MP, Cutrignelli A, Depalo N, et al. Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody￾Conjugated Liposomes in Colorectal Cancer In vitro Models. Pharmaceutics. 2020;12(7):650. doi:10.3390/pharmaceutics12070650
  98. Hamaguchi T, Matsumura Y, Nakanishi Y, et al. Antitumor effect of MCC‐465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 2004;95(7):608-613. doi:10.1111/j.1349-7006.2004.tb02495.x
  99. Chen M, Yu Y, Jiang F, et al. Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy. Int J Mol Sci. 2016;17(12):2079. doi:10.3390/ijms17122079
  100. Tombelli S, Minunni M, Mascini M. Analytical applications of aptamers. Biosens Bioelectron. 2005;20(12):2424-2434. doi:10.1016/j.bios.2004.11.006
  101. Jin B, Guo Z, Chen Z, et al. Aptamers in cancer therapy: problems and new breakthroughs. J Mater Chem B. 2023;11(8):1609-1627. doi:10.1039/D2TB02579E
  102. Moosavian SA, Kesharwani P, Singh V, Sahebkar A. Aptamer-functionalized liposomes for targeted cancer therapy. In: Aptamers Engineered Nanocarriers for Cancer Therapy. Elsevier; 2023:141-172. doi:10.1016/B978-0-323-85881-6.00014-2
  103. Khodarahmi M, Abbasi H, Kouchak M, Mahdavinia M, Handali S, Rahbar N. Nanoencapsulation of aptamer￾functionalized 5-Fluorouracil liposomes using alginate/chitosan complex as a novel targeting strategy for colon-specific drug delivery. J Drug Deliv Sci Technol. 2022;71:103299. doi:10.1016/j.jddst.2022.103299
  104. Aravind A, Jeyamohan P, Nair R, et al. AS1411 aptamer tagged PLGA‐lecithin‐PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng. 2012;109(11):2920-2931. doi:10.1002/bit.24558
  105. Li X, Wu X, Yang H, Li L, Ye Z, Rao Y. A nuclear targeted Dox￾aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer. Biomed Pharmacother. 2019;117:109072. doi:10.1016/j.biopha.2019.109072
  106. Tanzadehpanah H, Mahaki H, Manoochehri H, Soleimani M, Najafi R. AS1411 aptamer improves therapeutic efficacy of PEGylated nanoliposomes loaded with gefitinib in the mice bearing CT26 colon carcinoma. J Nanoparticle Res. 2022;24(12):252. doi:10.1007/s11051-022-05630-0
  107. Zhao Y, Xu J, Le VM, et al. EpCAM Aptamer-Functionalized Cationic Liposome-Based Nanoparticles Loaded with miR-139-5p for Targeted Therapy in Colorectal Cancer. Mol Pharm. 2019;16(11):4696-4710. doi:10.1021/acs.molpharmaceut.9b00867
  108. Song M, Yin Y, Zhang J, et al. MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. Protein Cell. 2014;5(11):851-861. doi:10.1007/s13238-014-0093-5
  109. Mashreghi M, Zamani P, Moosavian SA, Jaafari MR. Anti￾Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma. Nanoscale Res Lett. 2020;15(1):101. doi:10.1186/s11671-020-03334-9
  110. Kono K, Ozawa T, Yoshida T, et al. Highly temperature￾sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy. Biomaterials. 2010;31(27):7096-7105. doi:10.1016/j.biomaterials.2010.05.045
  111. Simões S. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev. 2004;56(7):947-965. doi:10.1016/j.addr.2003.10.038
  112. Leung SJ, Romanowski M. Light-Activated Content Release from Liposomes. Theranostics. 2012;2(10):1020-1036. doi:10.7150/thno.4847
  113. Nobuto H, Sugita T, Kubo T, et al. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer. 2004;109(4):627-635. doi:10.1002/ijc.20035
  114. Pradhan P, Giri J, Rieken F, et al. Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release. 2010;142(1):108-121. doi:10.1016/j.jconrel.2009.10.002
  115. Zangabad PS, Mirkiani S, Shahsavari S, et al. Stimulus￾responsive liposomes as smart nanoplatforms for drug delivery applications. Nanotechnol Rev. 2018;7(1):95-122. doi:10.1515/ntrev-2017-0154
  116. Yu C, Li L, Hu P, et al. Recent Advances in Stimulus‐Responsive Nanocarriers for Gene Therapy. Adv Sci. 2021;8(14):2100540. doi:10.1002/advs.202100540
  117. Lorente C, Cabeza L, Clares B, et al. Formulation and in vitro evaluation of magnetoliposomes as a potential nanotool in colorectal cancer therapy. Colloids Surfaces B Biointerfaces. 2018;171:553-565. doi:10.1016/j.colsurfb.2018.07.070
  118. Hardiansyah A, Huang L-Y, Yang M-C, et al. Magnetic liposomes for colorectal cancer cells therapy by high￾frequency magnetic field treatment. Nanoscale Res Lett. 2014;9(1):497. doi:10.1186/1556-276X-9-497
  119. Kuo C-Y, Liu T-Y, Chan T-Y, et al. Magnetically triggered nanovehicles for controlled drug release as a colorectal cancer therapy. Colloids Surfaces B Biointerfaces. 2016;140:567-573. doi:10.1016/j.colsurfb.2015.11.008
  120. Toro-Córdova A, Llaguno-Munive M, Jurado R, Garcia￾Lopez P. The Therapeutic Potential of Chemo/Thermotherapy with Magnetoliposomes for Cancer Treatment. Pharmaceutics. 2022;14(11):2443. doi:10.3390/pharmaceutics14112443
  121. Clares B, Biedma-Ortiz RA, Sáez-Fernández E, et al. Nano￾engineering of 5-fluorouracil-loaded magnetoliposomes for combined hyperthermia and chemotherapy against colon cancer. Eur J Pharm Biopharm. 2013;85(3):329-338. doi:10.1016/j.ejpb.2013.01.028
  122. Karanth H, Murthy RSR. pH-Sensitive liposomes-principle and application in cancer therapy. J Pharm Pharmacol. 2007;59(4):469-483. doi:10.1211/jpp.59.4.0001
  123. Paulmurugan R. Introduction to cancer biology. In: Molecular Imaging Probes for Cancer Research. World Scientific Publishing Co. Pte. Ltd.; 2012:3-27.
  124. Nunes SS, Miranda SEM, de Oliveira Silva J, et al. pH￾responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment. Biomed Pharmacother. 2021;144:112317. doi:10.1016/j.biopha.2021.112317
  125. Udofot O, Affram K, Israel B, Agyare E. Cytotoxicity of 5-fluorouracil-loaded pH-sensitive liposomal nanoparticles in colorectal cancer cell lines. Integr Cancer Sci Ther. 2015;2(5). doi:10.15761/ICST.1000150
  126. Wang G, Yang Y, Yi D, et al. Eudragit S100 prepared pH￾responsive liposomes-loaded betulinic acid against colorectal cancer in vitro and in vivo. J Liposome Res. 2022;32(3):250-264. doi:10.1080/08982104.2021.1999974
  127. Iranpour S, Bahrami AR, Sh. Saljooghi A, Matin MM. Application of smart nanoparticles as a potential platform for effective colorectal cancer therapy. Coord Chem Rev. 2021;442:213949. doi:10.1016/j.ccr.2021.213949
  128. Krasteva N, Georgieva M. Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials. Pharmaceutics. 2022;14(6):1213. doi:10.3390/pharmaceutics14061213
  129. Murphy N, Ward HA, Jenab M, et al. Heterogeneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: A Multinational Cohort Study. Clin Gastroenterol Hepatol. 2019;17(7):1323-1331.e6. doi:10.1016/j.cgh.2018.07.030
  130. Berry CC, Wells S, Charles S, Curtis ASG. Dextran and albumin derivatised iron oxide nanoparticles: influence on fibroblasts in vitro. Biomaterials. 2003;24(25):4551-4557. doi:10.1016/S0142-9612(03)00237-0
  131. Enrico C. Nanotechnology-Based Drug Delivery of Natural Compounds and Phytochemicals for the Treatment of Cancer and Other Diseases. In:; 2019:91-123. doi:10.1016/B978-0-444-64185-4.00003-4
  132. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an Emerging Platform for Cancer Therapy. In: Nano-Enabled Medical Applications.; 2020.
  133. Russo E, Scicchitano F, Whalley BJ, et al. Hypericum perforatum: Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug-Drug Interactions. Phyther Res. 2014;28(5):643-655. doi:10.1002/ptr.5050